# Danh sách chất
1. 3-((4H-benzo[d][1,3,2]dioxaborinin-2-yl)methyl)-1-(4-(benzyloxy)-3-methoxybenzyl)-2-methoxy-1,2-azaborolidine

2. 2-((2-methoxy-2,3-dihydrobenzo[d][1,2]oxaborol-3-yl)methyl)-4H-benzo[d][1,3,2]dioxaborinine

# Đích

# **1. PPARA (7BQ2)** `A:273, A:275, A:276, A:279`

### 🌟 4 Axit amin linh động BẮT BUỘC (Literature-Verified Tier)
Nhóm này giải quyết trực tiếp vấn đề chênh lệch kích thước (size-mismatch) để 2 chất của bạn có thể lọt được vào túi Arm III:

1. **Phe273 (Phenylalanine 273):** Đóng vai trò là "người gác cổng" (gatekeeper). Nó bắt buộc phải được phép lật/xoay (flip) để tạo khoảng trống cho cái đuôi *benzyloxy* rất dài của chất thứ nhất chui vào sâu trong túi kỵ nước.
2. **Cys275 (Cysteine 275)** và 
3. **Cys276 (Cysteine 276):** Đây là hai bản lề cơ học (mechanical hinges) của túi gắn kết PPARα. Việc cài đặt linh động 2 gốc này cho phép toàn bộ cấu trúc túi (LBD) phình to ra một cách tự nhiên để ôm trọn cấu trúc lõi *dioxaborinine* cồng kềnh của cả 2 chất. Nếu để cứng (rigid), phần mềm sẽ báo lỗi va chạm (steric clash).
4. **Thr279 (Threonine 279):** Đây là mỏ neo (anchor) cực kỳ quan trọng nằm sâu trong nhánh **Arm III**. Cấu trúc của Thr279 rất linh hoạt và sẽ tự động xoay để tạo liên kết hydro (trực tiếp hoặc qua cầu nối nước) với các nguyên tử O, N, B trên lõi phân tử của bạn, từ đó quyết định hoạt lực và độ chọn lọc cực cao.

# **2. PPARD (7WGN)** `A:253, A:287, A:413, A:437`

**Layer 1 — Core Insight**
Designing multi-target boronic ligands presents a topological challenge when navigating the promiscuous peroxisome proliferator-activated receptor (PPAR) ligand-binding domains. The 7WGN co-crystal structure demonstrates that pemafibrate binds the Y-shaped Center and Arm II/III regions of PPAR delta. To achieve efficacy, your size-mismatched azaborolidine and dioxaborinine molecules must satisfy the specific consensus hydrogen-bond network of PPAR delta while structurally displacing the spatial volume near helix 5.

**Layer 2 — Structural Explanation**
The literature does not explicitly classify discrete residues as "flexible" within the 7WGN dataset. We execute an adaption-tier protocol to define the obligatory dynamic coordinates for your bulky structures. First, your models must establish local plasticity at the consensus tetrad: Thr253, His287, His413, and Tyr437. These residues act as adaptive anchors that secure the ligand headgroup to stabilize the AF-2 helix 12. Second, structural accommodation in PPAR delta explicitly requires shifting the phenoxyalkyl-equivalent groups toward helix 5. Third, the binding pocket utilizes a water-mediated hydrogen bond or electrostatic interaction to stabilize the 2-aminobenzoxazole group. You must configure your docking grids to allow spatial adjustments at these precise locations to prevent steric clashes with your expansive benzyloxy and oxaborole units.

**Layer 3 — Full Technical Detail**

*External Map:* Fibrate cross-reactivity redefines therapeutic boundaries. Repurposing these molecules bridges dyslipidemia treatments directly to non-alcoholic fatty liver disease interventions. 
*Internal Map:* Receptor activation strictly requires aligning the ligand head with the AF-2 helix 12 consensus tetrad. Concurrently, the hydrophobic tail must occupy the specified Y-shaped Arm II/III geometry.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Pemafibrate functions as a structural pan-agonist across PPAR subtypes.** | Pemafibrate activates PPAR delta/gamma LBD-mediated transactivation, recruits coactivators, and physically binds PPAR delta/gamma LBDs. |, | High | Biochemical transactivation and co-crystallization successfully translate into physiological pan-agonism. | Pemafibrate requires concentrations three orders of magnitude higher to activate PPAR delta/gamma compared to PPAR alpha. |
| **PPAR delta imposes a unique spatial orientation on specific ligand substituents.** | In the 7WGN structure, the phenoxyalkyl group of pemafibrate is specifically pushed toward helix 5 within the PPAR delta pocket. | | High | Spatial deviation toward helix 5 is mandatory to resolve steric limitations unique to the delta subtype. | The fundamental Y-shaped binding geometry across the Center and Arm II/III regions remains largely identical across all three PPAR subtypes. |
| **AF-2 helix 12 stabilization requires a strict four-residue consensus network.** | Carboxylic groups stabilize AF-2 helix 12 formation through direct hydrogen bonds and electrostatic interactions with Thr253, His287, His413, and Tyr437 in PPAR delta. | | High | Boronic or carboxylic warheads must coordinate this exact tetrad to induce coactivator recruitment. | Fenofibric acid stabilizes PPAR delta thermostability but fails to functionally activate the receptor or produce cocrystals. |
| **Ligand efficacy demands hydrophobic interactions within the core pockets.** | Pemafibrate is further stabilized by extensive hydrophobic interactions within the LBDs of all PPARs. |, | Medium | Hydrophobic packing provides the primary thermodynamic driving force for complex formation. | Water-mediated hydrogen bonds actively participate in anchoring specific functional groups in PPAR delta. |

**Synthesis:** 
Modulating coordinate flexibility at the consensus tetrad dictates the boundary between partial agonism and highly selective receptor activation. The lack of specific structural flexibility forces compounds into inactive conformations. Fenofibric acid increases PPAR delta thermostability but fails to recruit coactivators, proving that simple binding does not guarantee functional activation. 

**Dispositive Closure:** 
When docking your 1,2-azaborolidine and dioxaborinine derivatives against 7WGN, you must mandate side-chain flexibility for Thr253, His287, His413, and Tyr437. You must direct your structural appendages toward the space bounded by helix 5. Failure to model this specific plasticity will yield false-negative collision errors.

# **3. PPARG (8ATY)** `A:288,A:342,A:259`

Traditional PPARγ therapeutics encounter a biological paradox. Maximal insulin sensitization intrinsically couples with severe pro-adipogenic adverse effects. Resolving this requires shifting focus toward noncanonical allosteric modulation. Topologically, the receptor achieves this via a secondary solvent-exposed cleft bounded by Helix 4, Helix 5, and the Omega loop. 

The conventional premise dictates that PPARγ activation strictly requires direct physical coordination of the Helix 12 AF-2 surface. This position fails because crystallographic evidence (PDB: 8ATZ) demonstrates that alternative site ligands stabilize the active Helix 12 conformation allosterically through the Omega-loop, entirely bypassing direct AF-2 contact. This conclusion would be invalidated if structural variants of your bulky azaborolidines fully occlude the orthosteric pocket while generating classical pro-adipogenic transcriptional profiles.

To properly dock your large 1,2-azaborolidine and dioxaborinine derivatives, you must target the alternative binding site. Static algorithms will fail to capture the required binding volume. You must implement the following literature-verified flexible residues.

### Literature-Tier Flexible Residues

1. **Arg288**: Acts as the primary electrostatic anchor in the alternative site. It dynamically shifts to form direct ionic interactions or water-mediated hydrogen bonds with polar moieties, such as boronic or oxaborole oxygen atoms.
2. **Ser342**: Provides essential backbone and side-chain hydrogen bonding. It shifts to stabilize complex aromatic extensions within the alternative pocket cleft.
3. **Glu259**: Regulates the solvent-exposed periphery. Its side chain establishes critical hydrogen bonds with secondary amines or ether oxygen linkers spanning the alternative pocket.
4. **Ser289, His449, and Tyr473**: The classical orthosteric triad. If your compounds exhibit multi-site occupancy (1:2 stoichiometry like JP85/Compound 1 in PDB 8ATY), these residues must adapt to stabilize the canonical interactions.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence (Low/Medium/High) | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **PPARγ accommodates simultaneous multi-ligand occupancy across distinct sites.** | The LBD permits orthosteric ligands (pioglitazone) and alternative site ligands (Compound 2) to bind concurrently (1:1:1 stoichiometry) without steric competition. | Arifi et al., 2023 | High | Concurrent binding generates synergistic allosteric stabilization rather than independent silent states. | Specific extended ligands (MRL-871) occupy boundary regions overlapping both pockets, blocking secondary ligand entry. |
| **Helix 12 (AF-2) stabilization does not require direct orthosteric contact.** | Compound 2 induces an active Helix 12 state solely through alternative site binding, likely propagated via Omega-loop stabilization. | Arifi et al., 2023 | High | Omega-loop ordering mechanically couples to Helix 12 inward dynamics. | Alternative site ligands like BVT.13 bind the pocket but fail to trigger the active Helix 12 inward swing. |
| **Selective alternative site modulation prevents canonical adipogenesis.** | Targeting the H4/H5 cleft avoids the classical pro-adipogenic gene transcription profiles (e.g., CPT-1, FABP1) triggered by TZD therapies. | Arifi et al., 2023 | High | *In vivo* cellular differentiation pathways directly mirror these *in vitro* mRNAseq hepatocyte profiles. | The alternative site ligand still retains baseline recruitment of select canonical co-activators like PGC-1α. |
| **Alternative site activation uniquely suppresses FOXO signaling.** | The noncanonical binding mode diminishes FOXO3 expression and enhances inactivating Ser253 phosphorylation, driving cells toward a resting state. | Arifi et al., 2023 | Medium | FOXO suppression operates exclusively through genomic PPARγ regulation rather than secondary kinase off-targets. | Orthosteric PPARγ agonists like pioglitazone exert zero regulatory influence on this specific FOXO pathway. |

**Dispositive Closure:**
Configure your docking grid to explicitly encompass the Helix 4/Helix 5 cleft. Mandate side-chain flexibility for Arg288, Glu259, and Ser342. Evaluate your boronic poses based on their ability to stabilize the Omega loop rather than relying exclusively on direct Helix 12 contacts. This topology defines the absolute boundary between classical adipogenesis and selective noncanonical modulation.

# 4. EGFR (1XKK) `A:742, A:753, A:766, A:830, A:832, A:834`

Designing kinase inhibitors with extended benzyloxy appendages presents a profound steric paradox when targeting the canonically narrow active state of the epidermal growth factor receptor (EGFR). 

**Layer 1 — Core Insight**
The 1XKK crystal structure demonstrates that bulky inhibitors resolve this geometrical paradox by stabilizing a distinct inactive conformation of the kinase. This conformation features a massively expanded back pocket generated by a ~9 Å spatial shift of the C-helix. To achieve valid binding poses for your extended azaborolidine and dioxaborinine derivatives, algorithms must exploit this specific inactive topology.

**Layer 2 — Structural Explanation (Adaption-Tier Flexible Residues)**
The crystallographic literature does not explicitly catalog residues as computationally "flexible," mandating an adaption-tier protocol to define the dynamic boundaries for your large molecules. The 3-fluorobenzyloxy group of GW572016 (Lapatinib) physically forces the C-helix outward, creating a deep hydrophobic cavity. Your 4-(benzyloxy)-3-methoxybenzyl moiety demands this exact volumetric expansion to bind successfully. Consequently, docking protocols must assign side-chain plasticity to the specific residues lining this expanded back pocket. We identify Met742, Leu753, Thr766, Thr830, Phe832, and Leu834 as mandatory flexible coordinates. Furthermore, the outward displacement of the C-helix abolishes the highly conserved Glu738-Lys721 salt bridge, forcing Lys721 to coordinate directly with Asp831 in the lower lobe. Supplying flexibility to the Lys721 and Asp831 side-chains ensures the docking algorithm can model this disrupted electrostatic network without triggering artifactual collision penalties. 

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, the dissociation half-life fundamentally dictates clinical efficacy. Inhibitors adopting the 1XKK inactive conformation exhibit a remarkably slow off-rate, quantified at 0.0023 per minute, yielding a complex half-life of 300 minutes. This slow dissociation sustains profound receptor down-regulation in tumor cells up to 96 hours after initial exposure, far surpassing the recovery rate observed with active-state inhibitors like OSI-774. Targeting the inactive conformation transforms a simple binding event into a sustained pharmacological intervention.

*Internal Map:* 
The logical architecture of this inhibition relies on a "switch-clamp-latch" regulatory mechanism. The primary ligand core anchors to the hinge region, establishing a critical hydrogen bond between the quinazoline N1 and the main chain NH of Met769. Concurrently, the extended tail penetrates the DFG motif (Asp831, Phe832) region, locking the activation loop into a Src-like inactive state. This structural rearrangement allows residues 971 to 980 of the COOH-terminal tail to form a helical segment that packs against the hinge, acting as a physical clamp that restricts further conformational mobility.

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Bulky benzyloxy-style tails strictly demand the inactive, C-helix shifted conformation.** | GW572016's 3-fluorobenzyloxy group requires a ~9 Å outward shift of the C-helix to form the necessary back pocket, occupying the space previously held by Met742 in the active state. | | High (Validated by 2.40 Å X-ray diffraction data) | The user's benzyloxy tail shares identical spatial requirements to the 3-fluorobenzyloxy moiety. | Small-molecule inhibitors (like OSI-774/Tarceva) bind the active-like state without displacing the C-helix. |
| **The conserved Glu738-Lys721 salt bridge must be broken to accommodate bulky ligands.** | The C-helix displacement abolishes this critical interaction, re-routing Lys721 to form a hydrogen bond with Asp831 in the lower lobe. | | High | Breaking this salt bridge is thermodynamically compensated by the extensive hydrophobic contacts of the bulky tail. | Active-state inhibitors strictly require the maintenance of the Glu738-Lys721 salt bridge for high affinity. |
| **Slow dissociation rates dictate prolonged biological efficacy.** | The inactive-state complex exhibits a 300-minute half-life, which correlates directly with 96-hour suppression of EGFR phosphorylation in HN5 cells. | | High | In vitro dissociation kinetics directly govern in vivo receptor autophosphorylation recovery rates. | Rapid off-rate inhibitors (OSI-774) still achieve high initial apoptosis despite 24-hour phosphorylation recovery. |
| **Inactive-state binding enables dual EGFR/ErbB-2 selectivity.** | GW572016 inhibits both EGFR (Ki 3 nM) and ErbB-2 (Ki 13 nM) identically. The shared ability to adopt this specific inactive conformation drives this dual profile. | | Medium | ErbB-2 cannot readily adopt the active-like conformation required by highly selective EGFR inhibitors. | Selective ErbB-2 inhibitors (CP-654577) exist, indicating alternative mechanisms for specific subtype targeting. |

**Synthesis:**
The prevailing counterposition assumes that active-state structures represent the optimal universal templates for kinase docking protocols. This premise fails because it ignores the profound steric limitations of the DFG-in/alpha-C-in conformation. Attempting to dock your bulky azaborolidine and dioxaborinine compounds into an active-state model will force the structural appendages into insurmountable steric clashes, artificially inflating the interaction energy. This conclusion would be invalidated if your derivative demonstrates sub-nanomolar affinity in a confirmed active-state crystal structure without inducing a C-helix displacement. 

**Dispositive Closure:**
When executing *in silico* docking for your specific boron-containing derivatives against the 1XKK structure, you must explicitly target the expanded back pocket. You are required to assign side-chain flexibility to Met742, Leu753, Thr766, Thr830, Phe832, Leu834, and the Lys721/Asp831 pair. Evaluate poses based strictly on their ability to occupy the volumetric space vacated by the shifted C-helix while preserving the core hinge interaction at Met769. This exact geometrical compliance defines the boundary between functional in silico prediction and artifactual docking failure.

# 5. ERBB2 (7PCD) `A:783, A:805, A:801, A:802`
Ser783, Cys805, Met801, and Pro802
Achieving HER2 selectivity without triggering dose-limiting epidermal growth factor receptor (EGFR) toxicity presents a profound structural paradox. 

**Layer 1 — Core Insight**
The 7PCD crystal structure resolves this paradox by exploiting a single amino acid variance in the hydrophobic back pocket. Highly selective inhibitors penetrate this space to engage Ser783, a residue uniquely present in HER2 compared to the homologous Cys775 in EGFR. To successfully dock your bulky, non-covalent azaborolidine and dioxaborinine derivatives, algorithms must exploit this specific selectivity filter while neutralizing the covalent constraints of the 7PCD template.

**Layer 2 — Structural Explanation (Adaption-Tier Flexible Residues)**
The 7PCD structure represents a covalently locked state. Your compounds lack an acrylamide warhead, mandating an adaption-tier protocol to define dynamic coordinates. First, you must assign flexibility to **Ser783**. This residue acts as the absolute selectivity determinant; its side-chain must rotate to accommodate your extended benzyloxy-methoxybenzyl tail within the back pocket. Second, mandate flexibility for **Cys805**. In 7PCD, Cys805 covalently binds the ligand, but for your massive boronic structures, this front-pocket residue must shift to prevent artifactual collision penalties. Third, establish plasticity at the hinge anchors **Met801** and **Pro802**. These residues must independently adjust to permit optimal hydrogen-bonding alignments with your heterocycles. 

**Layer 3 — Full Technical Detail**

*External Map:* 
In the broader therapeutic landscape, pan-ERBB inhibitors fail because EGFR inhibition drives severe toxicity before HER2 exon 20 insertion mutations are adequately suppressed. Targeting Ser783 bridges this therapeutic gap, allowing profound tumor regression without collateral wild-type EGFR impairment.

*Internal Map:* 
The logical architecture relies on anchoring the heterocyclic core at the Met801/Pro802 hinge while driving a rigid extension into the back pocket. Disruption of either the covalent anchor (via a Cys805Ser mutation) or the back-pocket anchor (via a Ser783Cys mutation) structurally abolishes inhibitor efficacy. 

### Argument-Evidence Map

| Argument | Supporting Citations/Explanation | Source + Location | Strength of Evidence | Assumption | Counter-Evidence |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **HER2 selectivity exclusively depends on back-pocket Ser783 engagement.** | A Ser783Cys mutation in HER2 eliminates inhibitor potency, while the reverse Cys775Ser mutation in EGFR drastically increases it. | Wilding et al., 2022 | High | The user's benzyloxy tail possesses sufficient length and appropriate geometry to penetrate the back pocket. | Ligands that fail to reach the back pocket cannot utilize this selectivity filter and act as pan-ERBB inhibitors. |
| **Cys805 governs front-pocket affinity and resistance mechanics.** | Cys805Ser mutations emerge as the dominant resistance mechanism against targeted covalent inhibitors during ENU mutagenesis screens. | Wilding et al., 2022 | High | Bulky boronic components occupy the exact spatial volume previously held by the acrylamide warhead. | Non-covalent inhibitors targeting allosteric pockets bypass Cys805 dependency entirely. |
| **Exon 20 insertion efficacy does not require mutant-specific docking templates.** | Wild-type HER2 surrogate structures (7PCD) accurately predict the binding efficacy of inhibitors tested against aggressive HER2YVMA exon 20 insertion mutants. | Wilding et al., 2022 | High | The wild-type ATP-cleft geometry structurally mirrors the functional state of the hyperactive exon 20 insertion mutant. | Specific exon 20 insertions could radically deform the alpha-C helix, invalidating the wild-type template. |

**Synthesis:**
The prevailing counterposition assumes that overcoming EGFR-mediated toxicity requires abandoning the highly conserved ATP-binding cleft in favor of allosteric sites. This premise fails because it ignores the profound discriminative power of the Ser783/Cys775 micro-variance. This conclusion would be invalidated if your bulky azaborolidine derivatives fully occlude the front pocket without penetrating the back pocket, rendering the Ser783 selectivity filter irrelevant. 

**Dispositive Closure:**
When executing *in silico* docking against 7PCD, you must explicitly disable any covalent bonding parameters. Mandate side-chain flexibility for Ser783, Cys805, Met801, and Pro802. Direct your extended benzyloxy appendages strictly into the back pocket toward Ser783. This exact geometrical compliance defines the absolute boundary between dose-limiting EGFR cross-reactivity and highly selective HER2 modulation.
